Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-117-2 | CAS number: 133-66-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 9.7 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 75
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 727 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- In the absence of absorption data, it is assumed that the modalities of absorption between animals and human are the same. Further, in absence of data, according to the R8 ECHA guidance, a default factor of 2 (i.e. the absorption percentage for the starting route is half that of the end route) in the case of oral-to-inhalation was applied, i.e. a 1: 2 relationship has been applied to convert the oral NOAEL into the corrected NOAEC. Moreover, the oral dose has been corrected by the standard respiration volume in rats for a period of 8 hours (standard working shift), and then it has been also corrected for the differences of the sRV of rats (at rest) and workers (at light activity). Corrected inhalation NOAEC = 825 mg/kg bw/day/2 x (1 / sRVrat) x (ABSoral rat / ABSinhalation rat) x (ABSinhalation rat / ABSinhalation human) x (sRVhuman / wRVhuman) = 825/2 mg/kg bw/day x (1 / 0.38 m3/kg bw/day) x (1 / 1) x (6.7 m3 (8 hours) / 10 m3 (8 hours)) = 727 mg/m3 In practical, to correct the interspecies difference between rat and human and applying the route-to.-route extrapolation the no observed effect level has to be corrected from 825 mg/m3 to 727 mg/m3.
- AF for differences in duration of exposure:
- 6
- Justification:
- from subacute to chronic
- AF for interspecies differences (allometric scaling):
- 2.5
- Justification:
- remaining interspecies differences
- AF for intraspecies differences:
- 5
- Justification:
- intraspecies differences: worker
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 27 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 300
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 8 250 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- The dermal route is typically covered by oral route information in the absence of data for this administration route. No data on skin penetration are available for the test article. However, since the test article has a molecular weight of > 500 and the estimated log POW is not within -1 to 4, a skin penetration of 10% can be assumed and an assessment factor of 0.1 is applied
- AF for differences in duration of exposure:
- 6
- Justification:
- from subacute to chronic
- AF for interspecies differences (allometric scaling):
- 2.5
- Justification:
- remaining interspecies differences
- AF for other interspecies differences:
- 4
- Justification:
- from rat to human
- AF for intraspecies differences:
- 5
- Justification:
- intraspecies differences: worker
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Identification of relevant dose descriptor
For the derivation of the DNELs, the 28 days feeding study in rats was qualified as the most relevant study. The dose descriptor chosen was the NOAEL of 825 ppm test substance in food (highest dose,subacute 28-day oral toxicity (gavage) study in the rat according to OECD 407 – 1991) measuredfor a structure analogue of 133-66-4 having CAS 16090-02-1. This study was considered the most relevant for the hazard assessment
Systemic, short-term, dermal and inhalative
According to the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterization of dose [concentration]-response for human health", a DNEL for acute systemic toxicity should only be derived if an acute systemic toxicity hazard leading to classification is identified. Therefore, because the substance is not classified for acute toxicity according to Directive 67/548/EEC and Regulation 1272/2008/EC, no systemic DNELs for short-term exposures were calculated
Local, long-term and short-term, dermal& inhalative
Based on the available key toxicological information, the test item is not subject to classification for skin and eye irritation and skin sensitization (according to 67/548/EEC and EC/1272/2008). Accordingly, no DNELs for local effects following acute/short-term or long-term exposure are derived. This is in line with the ECHA guidance document (Chapter R.8).
Systemic, long-term, inhalative
Because no inhalation study is available, a route to route extrapolation was performed. The NOAEL (oral) is converted into a NOAEC (corrected) in accordance to guidance on information requirements and chemical safety assessment, Chapter R.8, ECHA, November 2012.
In the absence of absorption data, it is assumed that the modalities of absorption between animals and human are the same. Further, in absence of data, according to the R8 ECHA guidance,a default factor of 2 (i.e. the absorption percentage for the starting route is half that of the end route) in the case of oral-to-inhalation was applied, i.e.a 1: 2 relationship has been applied to convert the oral NOAEL into the corrected NOAEC.
Moreover, the oral dose has been corrected by the standard respiration volume in rats for a period of 8 hours (standard working shift), and then it has been also corrected for the differences of the sRV of rats (at rest) and workers (at light activity). Corrected inhalation NOAEC = 825 mg/kg bw/day/2 x (1 / sRVrat) x (ABSoral rat / ABSinhalation rat) x (ABSinhalation rat / ABSinhalation human) x (sRVhuman / wRVhuman) = 825/2 mg/kg bw/day x (1 / 0.38 m3/kg bw/day) x (1 / 1) x (6.7 m3 (8 hours) / 10 m3 (8 hours)) = 727 mg/m3
In practical, to correct the interspecies difference between rat and human and applying the route-to.-route extrapolation the no observed effect level has to be corrected from 825 mg/m3to 727 mg/m3.
Thus, the corrected startingpoint for workers was 727 mg/m³ for inhalation.
Subsequently other assessment factors are listed, which have to be taken into account for the final DNEL calculation:
1) Exposure duration (from subacute to chronic) = (6)
2) remaining interspecies differences – allometric scaling (2.5);
3) intraspecies differences: worker (5);
Then, this results in an overall assessment factor of 75
The DNEL for long-term inhalative exposure, systemic effects is therefore 9,7 mg/m³.
Systemic, long-term, dermal:
The dermal route is typically covered by oral route information in the absence of data for this administration route. No data on skin penetration are available for the test article. However, since the test article has a molecular weight of > 500 and the estimated log POWis not within -1 to 4, a skin penetration of 10% can be assumed and an assessment factor of 0.1 is applied (ECHA GD chapter R7c).
Thus, the corrected starting point for workers was 8250 mg/kg for dermal route.
Subsequently other assessment factors are listed, which have to be taken into account for the final DNEL calculation:
1) Exposure duration (from subacute to chronic) = (6)
2) Interspecies differences (from rat to human) (4)
2) remaining interspecies differences – allometric scaling (2.5);
3) intraspecies differences: worker (5);
Then, this results in an overall assessment factor of 300
The resulting DNEL for long-term dermal systemic effects is 27 mg/kg for workers.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.4 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 150
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 359 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Because no inhalation study is available, a route to route extrapolation was performed. The NOAEL (oral) is converted into a NOAEC (corrected) in accordance to guidance on information requirements and chemical safety assessment, Chapter R.8, ECHA, November 2012. In the absence of absorption data, it is assumed that the modalities of absorption between animals and human are the same. Further, in absence of data, according to the R8 ECHA guidance, a default factor of 2 (i.e. the absorption percentage for the starting route is half that of the end route) in the case of oral-to-inhalation was applied, i.e. a 1: 2 relationship has been applied to convert the oral NOAEL into the NOAEC. To correct the interspecies difference between rat and human the no observed effect level has to be corrected as follows: Corrected starting point for the inhalative route for general population: NOAEL/2 * (1/1.15 m³/kg bw/day) Where: 1.15 m³/kg bw/day: default respiratory volume for the rat corresponding to the daily duration of human exposure.
- AF for differences in duration of exposure:
- 6
- Justification:
- from subacute to chronic
- AF for interspecies differences (allometric scaling):
- 2.5
- Justification:
- remaining interspecies differences
- AF for intraspecies differences:
- 10
- Justification:
- intraspecies differences: general population
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 13.8 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 600
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 8 250 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- The dermal route is typically covered by oral route information in the absence of data for this administration route. No data on skin penetration is available for the test article. However, since the test article has a molecular weight of > 500 and the log POW is not within -1 to 4, a skin penetration of 10% can be assumed and an assessment factor of 0,1 is applied (ECHA GD chapter R7c). Thus, the corrected starting point for the general population was 8250 mg/kg/d for dermal route.
- AF for differences in duration of exposure:
- 6
- Justification:
- from subacute to chronic
- AF for interspecies differences (allometric scaling):
- 2.5
- Justification:
- remaining interspecies differences
- AF for other interspecies differences:
- 4
- Justification:
- from rat to human
- AF for intraspecies differences:
- 10
- Justification:
- intraspecies differences: general population
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.4 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 600
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 825 mg/kg bw/day
- AF for differences in duration of exposure:
- 6
- Justification:
- from subacute to chronic
- AF for interspecies differences (allometric scaling):
- 2.5
- Justification:
- remaining interspecies differences
- AF for other interspecies differences:
- 4
- Justification:
- from rat to human)
- AF for intraspecies differences:
- 10
- Justification:
- intraspecies differences: general population
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Identification of relevant dose descriptor
The dose descriptor chosen is the same as for workers (see above). The NOAEL of 825 mg/kg observed in thesubacute 28-day oral toxicity (gavage) study in ratswas used as starting point to derive the DNELs.
Systemic, short-term, dermal and inhalative
According to the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterization of dose[concentration]-response for human health", a DNEL for acute systemic toxicity should only be derived if an acute systemic toxicity hazard leading to classification is identified. Therefore, because the substance is not classified for acute toxicity according to Directive 67/548/EEC and Regulation 1272/2008/EC, no systemic DNELs for short-term exposures were calculated.
Local, long-term and short-term, dermal& inhalative
Based on the available key toxicological information, the test item is not subject to classification for skin and eye irritation and skin sensitization (according to 67/548/EEC and EC/1272/2008). Accordingly, no DNELs for local effects following acute/short-term or long-term exposure are derived. This is in line with the ECHA guidance document (Chapter R.8).
Systemic, long-term, inhalative
Because no inhalation study is available, a route to route extrapolation was performed. The NOAEL (oral) is converted into a NOAEC (corrected) in accordance to guidance on information requirements and chemical safety assessment, Chapter R.8, ECHA, November 2012.
In the absence of absorption data, it is assumed that the modalities of absorption between animals and human are the same.Further, in absence of data, according to the R8 ECHA guidance,a default factor of 2 (i.e. the absorption percentage for the starting route is half that of the end route) in the case of oral-to-inhalation was applied, i.e.a 1: 2 relationship has been applied to convert the oral NOAEL into the NOAEC.
To correct the interspecies difference between rat and human the no observed effect level has to be corrected as follows:
Corrected starting point for the inhalative route forgeneral population:
NOAEL/2 * (1/1.15 m³/kg bw/day)
Where: 1.15 m³/kg bw/day: default respiratory volume for the rat corresponding to the daily duration of human exposure.
Thus, the corrected starting point for the general population, inhalative route, is 359 mg/m3
Subsequently other assessment factors are listed, which have to be taken into account for the final
1) Exposure duration (from subacute to chronic) = (6)
2) remaining interspecies differences – allometric scaling (2.5);
3) intraspecies differences: general population (10);
Then, this results in an overall assessment factor of 150.
The DNEL for long-term inhalative exposure, systemic effects is therefore considered to be 2,4 mg/m³.
Systemic, long-term, dermal:
The dermal route is typically covered by oral route information in the absence of data for this administration route. No data on skin penetration is available for the test article. However, since the test article has a molecular weight of > 500 and the log POW is not within -1 to 4, a skin penetration of 10% can be assumed and an assessment factor of 0,1 is applied (ECHA GD chapter R7c).
Thus, the corrected starting point for the general population was 8250 mg/kg/d for dermal route.
Subsequently other assessment factors are listed, which have to be taken into account for the final DNEL calculation:
1) Exposure duration (from subacute to chronic) = (6)
2) Interspecies differences (from rat to human) (4)
2) remaining interspecies differences – allometric scaling (2.5);
3) intraspecies differences: general population (10);
Then, this results in an overall assessment factor of 600
The DNEL for long-term dermal exposure, systemic effects is therefore considered to be 13,8 mg/kg.
Systemic, long-term, oral:
The NOAEL of 825 mg/kg observed in thesubacute 28-day oral toxicity (gavage) study in ratswas used as starting point to derive this DNEL.
For the overall assessment factor evaluation the following factors have to be taken into account for the final DNEL calculation:
1) Exposure duration (from subacute to chronic) = (6)
2) Interspecies differences (from rat to human) (4)
2) remaining interspecies differences – allometric scaling (2.5);
3) intraspecies differences: general population (10);
Then, this results in an overall assessment factor of 600
The resultingDNEL for long-term oral,systemic effects of the substance is 1,4 mg/kg for general population
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.